Today: 19 May 2026
NIO Stock Price Rises as Shares Buck Tesla-Led Selloff After First-Ever Profit
20 March 2026
1 min read

NIO Stock Price Rises as Shares Buck Tesla-Led Selloff After First-Ever Profit

NEW YORK, March 19, 2026, 19:13 EDT

NIO Inc. picked up 1.2% on Thursday, closing at $5.89 and snapping a two-day skid. The stock pulled ahead even as the Nasdaq slipped and Tesla lost ground. Trading volume landed at roughly 29.9 million shares, notably under its 50-day average—hinting traders weren’t rushing in just yet.

The move is significant, with investors watching to see if NIO’s debut quarterly net profit has staying power in a challenging market. Last week, the company guided for first-quarter deliveries between 80,000 and 83,000 units. Vehicle margin stood at 18.1% in Q4, measuring profit per vehicle sale before accounting for broader costs.

XPeng’s U.S. shares moved up 2.1%, Li Auto ticked 0.3% higher, but Tesla dropped 3.2% after American regulators expanded their investigation into the company’s Full Self-Driving system. NIO sat in between on a choppy day for EV stocks, holding up better than a lot of high-growth names.

NIO is banking on bigger scale, tighter costs, and getting more cars out of China in 2026. President Qin Lihong put a number on it, targeting overseas sales in the thousands this year. But Chief Executive William Li flagged a persistent headache—memory chips. According to Li, the chip crunch could hike costs by 6,000 yuan to 10,000 yuan per car, and in the worst scenario, even force a production halt.

Li reported record quarterly deliveries for NIO, ONVO, and FIREFLY in its March 10 earnings statement. CFO Stanley Yu Qu called the fourth quarter’s non-GAAP operating profit of 1.25 billion yuan “a major milestone” for operating performance, referring to the company’s own adjusted earnings metric. SEC

Analysts aren’t convinced the reset is finished. On March 13, HSBC’s Yuqian Ding bumped NIO up to Buy from Hold and raised her price target to $6.80, citing “better visibility” for 2026 volume growth and a clearer path to stronger earnings as the automaker’s next product cycle approaches. Investing.com

The upside isn’t a done deal. DBS analysts Raphael Wut Hei Tse and Elizabelle Pang stuck to their Hold rating as of March 13, pointing to “sector headwinds” that might counteract improved operating leverage. They flagged a potential slowdown in China’s auto market and tough competition as the big risks. DBS Bank

Thursday’s move higher has the feel of a reprieve rather than a decisive surge. NIO lags its 52-week high by 26.6%, and now the spotlight turns to March demand. The challenge: hit those first-quarter delivery goals without eroding margins.

Stock Market Today

  • Yimutian Inc. Receives Nasdaq Notice for Market Value Deficiency, Faces Potential Delisting
    May 19, 2026, 10:15 AM EDT. Yimutian Inc. (Nasdaq: YMT), a Chinese agricultural digital services firm, received a Nasdaq notification on May 13, 2026, for failing to meet the minimum market value of listed securities (MVLS) requirement of $50 million. This Nasdaq Listing Rule 5450(b)(2)(A) breach covers the period from March 25 to May 6, 2026. While this market value deficiency notice does not immediately affect the trading of Yimutian's American Depositary Shares (ADS) on the Nasdaq Global Market, it signals risk of delisting if not remedied. The company confirmed this event does not impact its business operations or reporting obligations with the U.S. Securities and Exchange Commission (SEC). The notice triggers a grace period for Yimutian to regain compliance or request a hearing to contest delisting.

Latest articles

Bakkt Up Early After Director Buys $4.85M in Shares

Bakkt Up Early After Director Buys $4.85M in Shares

19 May 2026
Bakkt shares jumped 14.2% to $9.96 in pre-market trading Tuesday after a filing showed director Michael Alfred’s vehicle bought $4.85 million in stock. SEC documents said Alfred acquired 585,000 shares last week via Alpine Fox LP. CEO Akshay Naheta exercised options for 33,557 shares at $10 each. Bakkt recently reported Q1 revenue of $243.6 million, down sharply from a year earlier.
Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

19 May 2026
Relay Therapeutics shares jumped 11.3% to $13.47 in premarket trading Tuesday after reporting a 60% volumetric response rate in 20 evaluable patients from its Phase 2 trial of zovegalisib for vascular anomalies. The company said 95% of patients saw some lesion reduction at 12 weeks. No patients discontinued due to adverse events. The regular Nasdaq session was set to open at 9:30 a.m. ET.

Popular

NAB share price falls 1.3% as oil shock and RBA risk hit National Australia Bank stock
Previous Story

NAB share price falls 1.3% as oil shock and RBA risk hit National Australia Bank stock

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy
Next Story

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Go toTop